Rare diseases

News

Alnylam to file gene-silencing porphyria drug

Alnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying its gene silencing technology to the condition for the first time, following suppor

Partner Content

$Banner for Media partners {460x250px}_3rd Genotoxic$

Partner Content

3rd Annual Impurities: Genotoxic and Beyond Summit

We are pleased to invite you to the 3rd Annual Impurities: Genotoxic and Beyond Summit scheduled for June 12th-13th, 2019.

Partner Content

$Banner for Media partners {460x250px}_4th Antibody Drug Conjugates$

Partner Content

4th Annual Antibody Drug Conjugates (ADC) Summit: From Targe...

We are pleased to invite you to the 4th Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 15-16, 2019 in Vienna, Austria.

Partner Content

$Banner for Media partners {460x250px}_3rd Antibody Bispecifics$

Partner Content

3rd Annual Antibody Summit: Bispecifics & Multispecifics

We are pleased to invite you to the 3rd Annual Antibody Summit: Biscpecifics & Multispecifics scheduled for May 15 - 16, 2019 in Vienna, Austria.

Partner Content

$Banner for Media partners {460x250px}_Gene and Cell Therapy$

Partner Content

Gene and Cell Therapy: Quality Developments to Commercializa...

We are pleased to invite you to the Annual Gene and Cell Therapy: Quality Developments to Commercialization Summit, scheduled for June 5-6, 2019, in Berlin, Germany.

Partner Content